SCHEMBL24378460

SCHEMBL24378460

Cc1cccc(-c2cn(C)c(C)n2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 1/20 0.50
RAB9A P51151 3/20 0.46
NPC1 O15118 2/20 0.46
KDM4E B2RXH2 1/20 0.46
KMO O15229 2/20 0.45
IDO1 P14902 1/20 0.45
METAP2 P50579 1/20 0.45
XDH P47989 1/20 0.43
BCHE P06276 1/20 0.42
ACHE P22303 1/20 0.42
ALDH1A1 P00352 1/20 0.42
NFKB1 P19838 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ENPP3 O14638 1/20 0.41
TP53 P04637 1/20 0.41
ATP4A P20648 1/20 0.40
ATP4B P51164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24740968 0.83 TLR8 (0.48) TLR8RAB9ANPC1KDM4EKMO
SCHEMBL8830111 0.81 KDM4E (0.49) TLR8RAB9ANPC1KDM4EALDH1A1
SCHEMBL26251829 0.80 TLR8 (0.46) TLR8RAB9ANPC1KDM4EKMO
SCHEMBL6718823 0.79 TLR8 (0.53) TLR8KDM4EKMOIDO1XDH
SCHEMBL22044982 0.79 TLR8 (0.35) TLR8RAB9ANPC1KDM4EKMO
SCHEMBL22045330 0.79 ALDH1A3 (0.36) TLR8RAB9ANPC1KDM4EALDH1A1
SCHEMBL7431062 0.78 KMO (0.52) TLR8RAB9ANPC1KDM4EKMO
SCHEMBL22434984 0.77 NPC1 (0.53) TLR8RAB9ANPC1KDM4EALDH1A1
SCHEMBL7430092 0.77 SCN9A (0.61) TLR8RAB9ANPC1KDM4EKMO
SCHEMBL12264968 0.77 RAB9A (0.54) TLR8RAB9ANPC1KDM4EKMO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018151-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME TME THERAPEUTICS LLC 2024-01-18 US disclosed
WO-2022086993-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME TME THERAPEUTICS LLC (US) 2022-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018151-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME PIKFYVE, PIK3CD, PIK3R5 TLR8 2801/4885RAB9A 1213/4885NPC1 2611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.